Pathobiology 2027

Mechanisms of Disease

May 1-4, 2027

Flamingo Las Vegas, Las Vegas, NW

Session 001 – Pathogenesis of MASH and Development of New Therapeutic Approaches

8:00-9:45 AM
Sponsored by the ASIP Liver Pathobiology Scientific Interest Group
Session Room: TBD

Session Co-Chairs

Vic Meadows

Vik Meadows, PhD
University of Pittsburgh School of Medicine

Satdarshan Paul Singh Monga

Satdarshan Paul Monga, MD
University of Pittsburgh School of Medicine

Kari Nejak-Bowen

Kari Nejak-Bowen, PhD
University of Pittsburgh School of Medicine

Session Overview

Metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease (ALD), and the overlapping MetALD represent a growing spectrum of chronic liver diseases driven by distinct, yet convergent, signaling pathways. Experts in this session will showcase the latest approaches to examine the mechanisms of hepatocyte injury, lipotoxicity, and fibrosis progression in these steatotic liver diseases. This session will highlight advances in multi-omics, models, and translational research that aid in understanding disease pathogenesis inform future therapies.

Agenda

  • Co-Chair – Welcome and Introductions

  • Bingning Dong8:00-8:25 AM
    The Role of LRH-1 in MASH
    Bingning Dong, PhD
    Baylor College of Medicine

  • Bin Gao8:25-8:50 AM
    Alcohol Metabolism in Pathogenesis of MetALD and ALD
    Bin Gao, MD, PhD
    National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health

  • Mark Miedel8:50-9:15 AM
    Patient-Derived Liver Microphysiological Systems for Precision Medicine in MASLD/MASH
    Mark Miedel, PhD
    University of Pittsburgh School of Medicine